PHAT
Phathom Pharmaceuticals, Inc.NASDAQHealthcare$11.34+1.80%ClosedMarket Cap: $893.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.89
P/S
5.10
EV/EBITDA
-15.61
DCF Value
$-6.23
FCF Yield
-18.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.1%
Operating Margin
-91.4%
Net Margin
-126.3%
ROE
55.1%
ROA
-85.4%
ROIC
-125.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $57.6M | 86.7% | $-5.9M | $-21.1M | $-0.29 | — |
| FY 2025 | $175.1M | 87.1% | $-160.0M | $-221.2M | $-3.03 | — |
| Q3 2025 | $49.5M | 87.5% | $-15.3M | $-30.0M | $-0.41 | — |
| Q2 2025 | $39.5M | 87.2% | $-59.9M | $-75.8M | $-1.05 | — |
| Q1 2025 | $28.5M | 86.9% | $-78.9M | $-94.3M | $-1.31 | — |
| Q4 2024 | $29.7M | 87.1% | $-59.4M | $-74.5M | $-1.05 | — |
| FY 2024 | $55.3M | 85.6% | $-277.5M | $-334.3M | $-5.29 | — |
| Q3 2024 | $16.4M | 85.6% | $-70.8M | $-85.6M | $-1.32 | — |
| Q2 2024 | $7.3M | 81.2% | $-77.3M | $-91.4M | $-1.56 | — |
| Q1 2024 | $1.9M | 77.7% | $-70.0M | $-82.9M | $-1.42 | — |
| Q4 2023 | $682.0K | 48.4% | $-69.9M | $-79.6M | $-1.39 | — |
| FY 2023 | $682.0K | 75.5% | $-167.3M | $-201.6M | $-3.93 | — |